HLA-A*26  ||| S:0 E:9 ||| NNP
and  ||| S:9 E:13 ||| CC
susceptility  ||| S:13 E:26 ||| NN
of  ||| S:26 E:29 ||| IN
iranian  ||| S:29 E:37 ||| JJ
patients  ||| S:37 E:46 ||| NNS
with  ||| S:46 E:51 ||| IN
non-Hodgkin  ||| S:51 E:63 ||| JJ
lymphoma  ||| S:63 E:72 ||| JJ
Non-Hodgkin  ||| S:72 E:84 ||| JJ
lymphoma  ||| S:84 E:93 ||| NNS
( ||| S:93 E:94 ||| -LRB-
NHL ||| S:94 E:97 ||| NNP
)  ||| S:97 E:99 ||| -RRB-
includes  ||| S:99 E:108 ||| VBZ
a  ||| S:108 E:110 ||| DT
wide  ||| S:110 E:115 ||| JJ
range  ||| S:115 E:121 ||| NN
of  ||| S:121 E:124 ||| IN
diseases  ||| S:124 E:133 ||| NNS
with  ||| S:133 E:138 ||| IN
different  ||| S:138 E:148 ||| JJ
clinical  ||| S:148 E:157 ||| JJ
and  ||| S:157 E:161 ||| CC
biological  ||| S:161 E:172 ||| JJ
features ||| S:172 E:180 ||| NNS
.  ||| S:180 E:182 ||| .
NHL  ||| S:182 E:186 ||| NNP
is  ||| S:186 E:189 ||| VBZ
usually  ||| S:189 E:197 ||| RB
presented  ||| S:197 E:207 ||| VBN
as  ||| S:207 E:210 ||| IN
localized  ||| S:210 E:220 ||| NN
or  ||| S:220 E:223 ||| CC
generalized  ||| S:223 E:235 ||| JJ
lymphadenopathy ||| S:235 E:250 ||| NN
.  ||| S:250 E:252 ||| .
It  ||| S:252 E:255 ||| PRP
has  ||| S:255 E:259 ||| VBZ
been  ||| S:259 E:264 ||| VBN
suggested  ||| S:264 E:274 ||| VBN
that  ||| S:274 E:279 ||| IN
the  ||| S:279 E:283 ||| DT
HLA  ||| S:283 E:287 ||| NNP
class  ||| S:287 E:293 ||| NN
I  ||| S:293 E:295 ||| PRP
and  ||| S:295 E:299 ||| CC
II  ||| S:299 E:302 ||| NNP
are  ||| S:302 E:306 ||| VBP
associated  ||| S:306 E:317 ||| VBN
with  ||| S:317 E:322 ||| IN
susceptibility  ||| S:322 E:337 ||| VBG
to  ||| S:337 E:340 ||| TO
NHL ||| S:340 E:343 ||| NNP
.  ||| S:343 E:345 ||| .
Different  ||| S:345 E:355 ||| JJ
ethnic  ||| S:355 E:362 ||| JJ
groups  ||| S:362 E:369 ||| NNS
have  ||| S:369 E:374 ||| VBP
been  ||| S:374 E:379 ||| VBN
found  ||| S:379 E:385 ||| VBN
to  ||| S:385 E:388 ||| TO
have  ||| S:388 E:393 ||| VB
different  ||| S:393 E:403 ||| JJ
HLA  ||| S:403 E:407 ||| NNP
class  ||| S:407 E:413 ||| NN
I  ||| S:413 E:415 ||| PRP
and  ||| S:415 E:419 ||| CC
II  ||| S:419 E:422 ||| NNP
alleles  ||| S:422 E:430 ||| NN
which  ||| S:430 E:436 ||| WDT
affect  ||| S:436 E:443 ||| VBP
NHL ||| S:443 E:446 ||| NNP
.  ||| S:446 E:448 ||| .
To  ||| S:448 E:451 ||| TO
evaluate  ||| S:451 E:460 ||| VB
the  ||| S:460 E:464 ||| DT
association  ||| S:464 E:476 ||| NN
of  ||| S:476 E:479 ||| IN
HLA  ||| S:479 E:483 ||| NNP
class  ||| S:483 E:489 ||| NN
I  ||| S:489 E:491 ||| PRP
and  ||| S:491 E:495 ||| CC
class  ||| S:495 E:501 ||| NN
II  ||| S:501 E:504 ||| NNP
with  ||| S:504 E:509 ||| IN
Non-Hodgkin ||| S:509 E:520 ||| NNP
's  ||| S:520 E:523 ||| POS
lymphoma  ||| S:523 E:532 ||| NN
in  ||| S:532 E:535 ||| IN
Iranian  ||| S:535 E:543 ||| JJ
patients ||| S:543 E:551 ||| NNS
.  ||| S:551 E:553 ||| .
We  ||| S:553 E:556 ||| PRP
performed  ||| S:556 E:566 ||| VBD
a  ||| S:566 E:568 ||| DT
case-control  ||| S:568 E:581 ||| JJ
genotyping  ||| S:581 E:592 ||| JJ
study  ||| S:592 E:598 ||| NN
on  ||| S:598 E:601 ||| IN
75  ||| S:601 E:604 ||| CD
Iranian  ||| S:604 E:612 ||| JJ
NHL  ||| S:612 E:616 ||| NN
patients  ||| S:616 E:625 ||| NNS
who  ||| S:625 E:629 ||| WP
were  ||| S:629 E:634 ||| VBD
selected  ||| S:634 E:643 ||| VBN
from  ||| S:643 E:648 ||| IN
among  ||| S:648 E:654 ||| IN
the  ||| S:654 E:658 ||| DT
patients  ||| S:658 E:667 ||| NNS
referred  ||| S:667 E:676 ||| VBD
to  ||| S:676 E:679 ||| TO
the  ||| S:679 E:683 ||| DT
Bone  ||| S:683 E:688 ||| NNP
Marrow  ||| S:688 E:695 ||| NNP
Transplantation  ||| S:695 E:711 ||| NNP
Department  ||| S:711 E:722 ||| NNP
of  ||| S:722 E:725 ||| IN
Taleghani  ||| S:725 E:735 ||| NNP
Hospital  ||| S:735 E:744 ||| NNP
and  ||| S:744 E:748 ||| CC
120  ||| S:748 E:752 ||| CD
apparently  ||| S:752 E:763 ||| RB
healthy  ||| S:763 E:771 ||| JJ
control  ||| S:771 E:779 ||| NN
subjects  ||| S:779 E:788 ||| NNS
using  ||| S:788 E:794 ||| VBG
the  ||| S:794 E:798 ||| DT
SSP-PCR  ||| S:798 E:806 ||| JJ
by  ||| S:806 E:809 ||| IN
a  ||| S:809 E:811 ||| DT
commercial  ||| S:811 E:822 ||| JJ
kit ||| S:822 E:825 ||| NN
.  ||| S:825 E:827 ||| .
Our  ||| S:827 E:831 ||| PRP$
results  ||| S:831 E:839 ||| NNS
demonstrated  ||| S:839 E:852 ||| VBN
that  ||| S:852 E:857 ||| IN
the  ||| S:857 E:861 ||| DT
HLA-A*26  ||| S:861 E:870 ||| NNP
( ||| S:870 E:871 ||| -LRB-
p ||| S:871 E:872 ||| NN
:  ||| S:872 E:874 ||| :
0.026 ||| S:874 E:879 ||| CD
;  ||| S:879 E:881 ||| :
OR ||| S:881 E:883 ||| NNP
:  ||| S:883 E:885 ||| :
8.5 ||| S:885 E:888 ||| CD
)  ||| S:888 E:890 ||| -RRB-
and  ||| S:890 E:894 ||| CC
HLA-B*35  ||| S:894 E:903 ||| NNP
( ||| S:903 E:904 ||| -LRB-
p ||| S:904 E:905 ||| NN
:  ||| S:905 E:907 ||| :
0.022 ||| S:907 E:912 ||| CD
;  ||| S:912 E:914 ||| :
OR ||| S:914 E:916 ||| NNP
:  ||| S:916 E:918 ||| :
0.375 ||| S:918 E:923 ||| CD
)  ||| S:923 E:925 ||| -RRB-
alleles  ||| S:925 E:933 ||| NN
had  ||| S:933 E:937 ||| VBD
positive  ||| S:937 E:946 ||| JJ
and  ||| S:946 E:950 ||| CC
negative  ||| S:950 E:959 ||| JJ
associations  ||| S:959 E:972 ||| NNS
with  ||| S:972 E:977 ||| IN
NHL  ||| S:977 E:981 ||| NNP
disease ||| S:981 E:988 ||| NN
,  ||| S:988 E:990 ||| ,
respectively ||| S:990 E:1002 ||| RB
.  ||| S:1002 E:1004 ||| .
HLA-DRB1*13  ||| S:1004 E:1016 ||| NNP
allele  ||| S:1016 E:1023 ||| NN
showed  ||| S:1023 E:1030 ||| VBD
decrease  ||| S:1030 E:1039 ||| NN
of  ||| S:1039 E:1042 ||| IN
frequency  ||| S:1042 E:1052 ||| NN
in  ||| S:1052 E:1055 ||| IN
patients  ||| S:1055 E:1064 ||| NNS
in  ||| S:1064 E:1067 ||| IN
comparison  ||| S:1067 E:1078 ||| NN
with  ||| S:1078 E:1083 ||| IN
the  ||| S:1083 E:1087 ||| DT
controls ||| S:1087 E:1095 ||| NNS
,  ||| S:1095 E:1097 ||| ,
but  ||| S:1097 E:1101 ||| CC
it  ||| S:1101 E:1104 ||| PRP
did  ||| S:1104 E:1108 ||| VBD
not  ||| S:1108 E:1112 ||| RB
remain  ||| S:1112 E:1119 ||| VB
significant  ||| S:1119 E:1131 ||| JJ
after  ||| S:1131 E:1137 ||| IN
correction ||| S:1137 E:1147 ||| NN
.  ||| S:1147 E:1149 ||| .
Our  ||| S:1149 E:1153 ||| PRP$
results  ||| S:1153 E:1161 ||| NNS
conclude  ||| S:1161 E:1170 ||| VBP
that  ||| S:1170 E:1175 ||| IN
HLA-A*26  ||| S:1175 E:1184 ||| NNP
may  ||| S:1184 E:1188 ||| MD
represent  ||| S:1188 E:1198 ||| VB
as  ||| S:1198 E:1201 ||| IN
a  ||| S:1201 E:1203 ||| DT
genetic  ||| S:1203 E:1211 ||| JJ
susceptibility  ||| S:1211 E:1226 ||| JJ
factors  ||| S:1226 E:1234 ||| NNS
in  ||| S:1234 E:1237 ||| IN
Iranian  ||| S:1237 E:1245 ||| JJ
patients  ||| S:1245 E:1254 ||| NNS
with  ||| S:1254 E:1259 ||| IN
Non-Hodgkin ||| S:1259 E:1270 ||| NNP
's  ||| S:1270 E:1273 ||| POS
lymphoma ||| S:1273 E:1281 ||| NN
,  ||| S:1281 E:1283 ||| ,
a  ||| S:1283 E:1285 ||| DT
finding  ||| S:1285 E:1293 ||| NN
which  ||| S:1293 E:1299 ||| WDT
generally  ||| S:1299 E:1309 ||| RB
supports  ||| S:1309 E:1318 ||| VBZ
contribution  ||| S:1318 E:1331 ||| NN
of  ||| S:1331 E:1334 ||| IN
genetic  ||| S:1334 E:1342 ||| JJ
factors  ||| S:1342 E:1350 ||| NNS
in  ||| S:1350 E:1353 ||| IN
the  ||| S:1353 E:1357 ||| DT
etiology  ||| S:1357 E:1366 ||| NN
of  ||| S:1366 E:1369 ||| IN
this  ||| S:1369 E:1374 ||| DT
disorder ||| S:1374 E:1382 ||| NN
.  ||| S:1382 E:1384 ||| .
In  ||| S:1384 E:1387 ||| IN
addition ||| S:1387 E:1395 ||| NN
,  ||| S:1395 E:1397 ||| ,
these  ||| S:1397 E:1403 ||| DT
results  ||| S:1403 E:1411 ||| NNS
may  ||| S:1411 E:1415 ||| MD
be  ||| S:1415 E:1418 ||| VB
useful  ||| S:1418 E:1425 ||| JJ
in  ||| S:1425 E:1428 ||| IN
designing  ||| S:1428 E:1438 ||| VBG
a  ||| S:1438 E:1440 ||| DT
peptide  ||| S:1440 E:1448 ||| NN
based  ||| S:1448 E:1454 ||| VBN
vaccine  ||| S:1454 E:1462 ||| NN
for  ||| S:1462 E:1466 ||| IN
the  ||| S:1466 E:1470 ||| DT
Iranian  ||| S:1470 E:1478 ||| JJ
NHL  ||| S:1478 E:1482 ||| NN
patients  ||| S:1482 E:1491 ||| NNS
with  ||| S:1491 E:1496 ||| IN
HLA-A*26 ||| S:1496 E:1504 ||| CD
.  ||| S:1504 E:1506 ||| .
